Defining the therapeutic window in a severe animal model of spinal muscular atrophy

Human Molecular Genetics

Volumn 23, Issue 17, 2014, Pages 4559-4568

  Robbins, Kate L ^a   Glascock, Jacqueline J ^a,b   Osman, Erkan Y ^a,b   Miller, Madeline R ^a   Lorson, Christian L ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIFESPAN; MOTOR PERFORMANCE; MOUSE; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; SPINAL MUSCULAR ATROPHY; SURVIVAL; TRICEPS BRACHII MUSCLE; VIRUS EXPRESSION; VIRUS PARTICLE; WEIGHT GAIN; WESTERN BLOTTING; ADMINISTRATION AND DOSAGE; ANIMAL; BODY WEIGHT; CHICKEN; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; HEK293 CELL LINE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MOTOR ACTIVITY; MUSCULAR ATROPHY, SPINAL; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; SKELETAL MUSCLE; TIME;

ANIMALS; BODY WEIGHT; CHICKENS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; INJECTIONS, INTRAVENTRICULAR; MICE; MOTOR ACTIVITY; MUSCLE, SKELETAL; MUSCULAR ATROPHY, SPINAL; NEUROMUSCULAR JUNCTION; PHENOTYPE; SURVIVAL ANALYSIS; SURVIVAL OF MOTOR NEURON 1 PROTEIN; TIME FACTORS;

EID: 84902577636     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu169     Document Type: Article

References (32)

1. Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M. et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80, 155-165.
2. Lorson, C.L., Hahnen, E., Androphy, E.J. and Wirth, B. (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA, 96, 6307-6311.
3. Lorson, C.L. and Androphy, E.J. (2000) An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum. Mol. Genet., 9, 259-265.
4. Lorson, C.L., Strasswimmer, J., Yao, J.M., Baleja, J.D., Hahnen, E., Wirth, B., Le, T., Burghes, A.H. and Androphy, E.J. (1998) SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet., 19, 63-66.
5. Pellizzoni, L., Charroux, B. and Dreyfuss, G. (1999)SMNmutants of spinal muscular atrophy patients are defective in binding to snRNP proteins. Proc. Natl Acad. Sci. USA, 96, 11167 -11172.
6. Burnett, B.G., Munoz, E., Tandon, A., Kwon, D.Y., Sumner, C.J. and Fischbeck, K.H. (2009) Regulation of SMN protein stability. Mol. Cell. Biol., 29, 1107-1115.
7. Feldkotter, M., Schwarzer, V., Wirth, R., Wienker, T.F. and Wirth, B. (2002) Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet., 70, 358-368.
8. Lotti, F., Imlach, W.L., Saieva, L., Beck, E.S., Hao le, T., Li, D.K., Jiao, W., Mentis, G.Z., Beattie, C.E., McCabe, B.D. et al. (2012) An SMN-Dependent U12 splicing event essential for motor circuit function. Cell, 151, 440-454.
9. Fallini, C., Bassell, G.J. and Rossoll,W.(2012) Spinal muscular atrophy: the role of SMN in axonal mRNA regulation. Brain Res., 1462, 81-92.
10. Lorson, M.A. and Lorson, C.L. (2012) SMN-inducing compounds for the treatment of spinal muscular atrophy. Future Med. Chem., 4, 2067-2084.
11. Le, T.T., McGovern, V.L., Alwine, I.E., Wang, X., Massoni-Laporte, A., Rich, M.M. and Burghes, A.H. (2011) Temporal requirement for high SMN expression in SMA mice. Hum. Mol. Genet., 20, 3578-3591.
12. Lutz, C.M., Kariya, S., Patruni, S., Osborne, M.A., Liu, D., Henderson, C.E., Li, D.K., Pellizzoni, L., Rojas, J., Valenzuela, D.M. et al. (2011) Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J. Clin. Invest., 121, 3029-3041.
13. Benkhelifa-Ziyyat, S., Besse, A., Roda, M., Duque, S., Astord, S., Carcenac, R., Marais, T. and Barkats, M. (2013) Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol. Ther., 21, 282-290.
14. Dominguez, E., Marais, T., Chatauret, N., Benkhelifa-Ziyyat, S., Duque, S., Ravassard, P., Carcenac, R., Astord, S., Pereira de Moura, A., Voit, T. et al. (2011) Intravenous scAAV9delivery of a codon-optimized SMN1sequence rescues SMA mice. Hum. Mol. Genet., 20, 681-693.
15. Foust, K.D., Wang, X., McGovern, V.L., Braun, L., Bevan, A.K., Haidet, A.M., Le, T.T., Morales, P.R., Rich, M.M., Burghes, A.H. et al. (2010) Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol., 28, 271-274.
16. Glascock, J.J., Shababi, M., Wetz, M.J., Krogman, M.M. and Lorson, C.L. (2012) Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy. Biochem. Biophys. Res. Commun., 417, 376-381.
17. Glascock, J.J., Osman, E.Y., Wetz, M.J., Krogman, M.M., Shababi, M. and Lorson, C.L. (2012) Decreasing disease severity in symptomatic, Smn(2/2);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery. Hum. Gene. Ther., 23, 330-335.
18. Passini, M.A., Bu, J., Richards, A.M., Kinnecom, C., Sardi, S.P., Stanek, L.M., Hua, Y., Rigo, F., Matson, J., Hung, G. et al. (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med., 3, 72ra18.
19. Valori, C.F., Ning, K., Wyles, M., Mead, R.J., Grierson, A.J., Shaw, P.J. and Azzouz, M. (2010) Systemic delivery of scAAV9 expressingSMNprolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med., 2, 35-42.
20. Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.M., Fyfe, J., Moullier, P., Colle, M.A. and Barkats, M. (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther., 17, 1187-1196.
21. Foust, K.D., Nurre, E., Montgomery, C.L., Hernandez, A., Chan, C.M. and Kaspar, B.K. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol., 27, 59-65.
22. McCarty, D.M., Fu, H., Monahan, P.E., Toulson, C.E., Naik, P. and Samulski, R.J. (2003) Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther., 10, 2112-2118.
23. Butchbach, M.E., Edwards, J.D. and Burghes, A.H. (2007) Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol. Dis., 27, 207-219.
24. Porensky, P.N., Mitrpant, C., McGovern, V.L., Bevan, A.K., Foust, K.D., Kaspar, B.K., Wilton, S.D. and Burghes, A.H. (2012) A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet., 21, 1625-1638.
25. Osman, E.Y., Yen, P.F. and Lorson, C.L. (2012) Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. Mol. Ther., 20, 119-126.
26. Hamilton, G. and Gillingwater, T.H. (2013) Spinal muscular atrophy: going beyond the motor neuron. Trends Mol. Med., 19, 40-50.
27. Hunter, G., Aghamaleky Sarvestany, A., Roche, S.L., Symes, R.C. and Gillingwater, T.H. (2014) SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. Hum. Mol. Genet., 23, 2235-2250.
28. McGivern, J.V., Patitucci, T.N., Nord, J.A., Barabas, M.E., Stucky, C.L. and Ebert, A.D. (2013) Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia, 61, 1418-1428.
29. Kariya, S., Park, G.H., Maeno-Hikichi, Y., Leykekhman, O., Lutz, C., Arkovitz, M.S., Landmesser, L.T. and Monani, U.R. (2008) Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet., 17, 2552-2569.
30. Murray, L.M., Comley, L.H., Thomson, D., Parkinson, N., Talbot, K. and Gillingwater, T.H. (2008) Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum. Mol. Genet., 17, 949-962.
31. Grieger, J.C., Choi, V.W. and Samulski, R.J. (2006) Production and characterization of adeno-associated viral vectors. Nat. Protoc., 1, 1412-1428.
32. Ling, K.K., Gibbs, R.M., Feng, Z. and Ko, C.P. (2012) Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Hum. Mol. Genet., 21, 185-195.